The Gamida Cell Chronicles: Diary of a Clinical Adventure

Yael Margolin, Gamida joined us last year at the World Stem Cells & Regenerative Medicine Congress to present on ‘The Gamida Cell Chronicles: Diary of a Clinical Adventure.’ Download this presentation now to find out more about: Promising Pipeline of Stem Cell Therapies Target Market in Hematological Malignancies Umbilical Cord Blood (UCB) is an Alternative Source of Hematopoietic Stem Cells …

New inward investment brings innovative cancer cell therapy to Scotland

“New inward investment brings innovative cancer cell therapy to Scotland supported by £500,000 Regional Selective Assistance Start-up biotechnology company, TC BioPharm Ltd (TCB), is announcing a strategic collaboration with MEDINET, a Tokyo-listed immuno-cell therapy company, to develop a novel treatment for various different types of cancer. MEDINET will exclusively license its innovative cell therapy technology to TC Biopharm for clinical …

Download Manufacturing Flexibility – Understanding scale up for your Cell Therapy

Richard Grant, Invetech joined us last year at the World Stem Cells & Regenerative Medicine Congress to present on ‘Manufacturing Flexibility – Understanding scale up for your Cell Therapy.’ Download this presentation now to find out more about: Commercialisation of a Cell Therapy is all about balance. Is your current process under control and scalable? What are the priorities for …

Tantalising results: A summary of the World Stem Cells and Regenerative Medicine Congress 2013

The conference hall at Victoria Park Plaza, London, UK was humming with the buzz you might expect as thought-leaders in the stem cell and regenerative medicine field congregated for the 8th annual World Stem Cells and Regenerative Medicine Congress Europe 2013. As several speakers were to note over the coming three days, it is an extremely exciting time for regenerative …

Trends in Regenerative Medicine Late Stage Clinical Development

Late stage clinical development was the flavour of the afternoon on Day One of the World Stem Cells and Regenerative Medicine Congress Europe 2013. Dolores Baksh, Director of R&D at Organogenesis spoke on "Improving product development efficiency using scientific, risk-based approaches". Key to her talk was the implementation of Quality by Design (QbD) principles to give a systematic, scientific, risk-based …

Guest Blog Autologous Cell Therapy can treat Tendinopathy

World Stem Cells and Regenerative Medicine Congress London 2013: An example of a successful regenerative medicine company is the Austalian Orthocell. The company formed in 2007 as a spun out from Western Australia University and is now successfully treating patients suffering from tendon, cartilage and soft tissue damage. Initially focused on musculoskeletal regenerative medicine, Orthocell has now developed a scale …

Guest Blog: Predictive surrogate assays for potency could drive efficient clinical translation and commercialization

The Centre for Commercialization of Regenerative Medicine (CCRM) envisages its mission in filling the main bottlenecks that a cell therapy product encounters because of the present gap between the existing government programs and the industry investment capital. Michael May, CCRM President and CEO, explained at the World Stem Cells and Regenerative Medicine Congress London 2013 how the company mission connects …

Guest Blog: Critical stability and Bioprocess consensus for manufacturing, storage and clinical delivery of cell and tissue products

Aby Mathew, Senior Vice President and Chief Technology Officer at BioLife Solutions, spoke at the World Stem Cells and Regenerative Medicine Congress London 2013 and gave us some heads up about the importance of ensuring biopreservation at all levels (upstream and downstream) of the bioprocess for the successful commercialization of cell therapy products. He said: "Biopreservation is vital for clinical …

Guest Blog: EU Ban on Animal Testing in Cosmetics Spurs Stem Cell Derived Toxicity Assay Development

On day 2 of the World Stem Cell Congress 2013 in London Dr. Marc Peschanski head of the Institute for Stem cell Therapy and Exploration on Monogenic diseases1 (i-STEM) addressed the congress attendees on the recent challenges and achievements of the ‘Stem Cells for a relevant, Efficient, Extended and normalized Toxicology2' (SCR & Tox) programme he directs. SCR & Tox …